3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Dermatologic
2
Thoracic
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
86
Lung Neoplasms
32
Small Cell Lung Carcinoma
18
Melanoma
17
Mesothelioma
13
Neoplasms
11
Colorectal Neoplasms
9
Carcinoma, Renal Cell
9
Squamous Cell Carcinoma of Head and Neck
7
Neoplasm Metastasis
7
Mesothelioma, Malignant
7
Carcinoma, Transitional Cell
7
Ovarian Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Liver Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Kidney Neoplasms
4
Brain Neoplasms
4
Carcinoma, Merkel Cell
3
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Interventions
Docetaxel
8
pembrolizumab
7
Pemetrexed
5
Carboplatin
5
Erlotinib Hydrochloride
4
toripalimab
3
rociletinib
3
fludarabine
3
Radiosurgery
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Gemcitabine
3
Etoposide
3
Cyclophosphamide
3
Cisplatin
3
Bevacizumab
3
lorlatinib
2
atezolizumab
2
Vinorelbine
2
Topotecan
2
Radiotherapy
2
Platinum
2
Itraconazole
2
Irinotecan
2
Interleukin-2
2
Cetuximab
2
Albumin-Bound Paclitaxel
2
vinflunine
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Ipilimumab
×
Thoracic
×
Clear all
NCT04855929
2024-11-08
ANV419-001
Anaveon AG
Phase 1
Completed
55 enrolled